RT Journal Article SR Electronic T1 Understanding the effectiveness of government interventions in Europe’s second wave of COVID-19 JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.03.25.21254330 DO 10.1101/2021.03.25.21254330 A1 Sharma, Mrinank A1 Mindermann, Sören A1 Rogers-Smith, Charlie A1 Leech, Gavin A1 Snodin, Benedict A1 Ahuja, Janvi A1 Sandbrink, Jonas B. A1 Monrad, Joshua Teperowski A1 Altman, George A1 Dhaliwal, Gurpreet A1 Finnveden, Lukas A1 Norman, Alexander John A1 Oehm, Sebastian B. A1 Sandkühler, Julia Fabienne A1 Mellan, Thomas A1 Kulveit, Jan A1 Chindelevitch, Leonid A1 Flaxman, Seth A1 Gal, Yarin A1 Mishra, Swapnil A1 Brauner, Jan Markus A1 Bhatt, Samir YR 2021 UL http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254330.abstract AB As European governments face resurging waves of COVID-19, non-pharmaceutical interventions (NPIs) continue to be the primary tool for infection control. However, updated estimates of their relative effectiveness have been absent for Europe’s second wave, largely due to a lack of collated data that considers the increased subnational variation and diversity of NPIs. We collect the largest dataset of NPI implementation dates in Europe, spanning 114 subnational areas in 7 countries, with a systematic categorisation of interventions tailored to the second wave. Using a hierarchical Bayesian transmission model, we estimate the effectiveness of 17 NPIs from local case and death data. We manually validate the data, address limitations in modelling from previous studies, and extensively test the robustness of our estimates. The combined effect of all NPIs was smaller relative to estimates from the first half of 2020, indicating the strong influence of safety measures and individual protective behaviours--such as distancing--that persisted after the first wave. Closing specific businesses was highly effective. Gathering restrictions were highly effective but only for the strictest limits. We find smaller effects for closing educational institutions compared to the first wave, suggesting that safer operation of schools was possible with a set of stringent safety measures including testing and tracing, preventing mixing, and smaller classes. These results underscore that effectiveness estimates from the early stage of an epidemic are measured relative to pre-pandemic behaviour. Updated estimates are required to inform policy in an ongoing pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementM. Sharma was supported by the EPSRC Centre for Doctoral Training in Autonomous Intelligent Machines and Systems (EP/S024050/1) and a grant from the EA Funds programme. S. Mindermann's funding for graduate studies was from Oxford University and DeepMind. C. Rogers-Smith was supported by a grant from Open Philanthropy. A.J. Norman was supported by the U.K. BBSRC and Open Philanthropy. J Ahuja was supported by Open Philanthropy. J. T. Monrad was supported by the Augustinus Foundation, the Knud Hojgaard Foundation, the William Demant Foundation, the Kai Lange and Gunhild Kai Lange Foundation, and the Aage and Johanne Louis-Hansen Foundation. G.Leech was supported by the UKRI Centre for Doctoral Training in Interactive Artificial Intelligence (EP/S022937/1). S.B. Oehm was supported by the Boehringer Ingelheim Fonds. L.Chindelevitch and S.Bhatt acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (MR/R015600/1), jointly funded by the U.K. Medical Research Council (MRC) and the U.K. Foreign, Commonwealth and Development Office (FCDO), under the MRC/FCDO Concordat agreement; are part of the EDCTP2 program supported by the European Union; and acknowledge funding by Community Jameel. S. Flaxman acknowledges the EPSRC (EP/V002910/1) and the Imperial College COVID-19 Research Fund. J.M. Brauner was supported by the EPSRC Centre for Doctoral Training in Autonomous Intelligent Machines and Systems (EP/S024050/1) and by Cancer Research UK. S. Bhatt acknowledges The UK Research and Innovation (MR/V038109/1), the Academy of Medical Sciences Springboard Award (SBF004/1080), The MRC (MR/R015600/1), The BMGF (OPP1197730), Imperial College Healthcare NHS Trust- BRC Funding (RDA02), The Novo Nordisk Young Investigator Award (NNF20OC0059309) and The NIHR Health Protection Research Unit in Modelling Methodology. S. Bhatt thanks Microsoft AI for Health and Amazon AWS for computational credits. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No approval required for research on public, fully anonymised data, as per the Central University Research Ethics Committee (CUREC) of the University of Oxford. https://researchsupport.admin.ox.ac.uk/governance/ethics/applyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request